TIL for Patients With Advanced Solid Tumor
- Disease/Condition
- Advanced Solid Tumor
- Drug/Device/Intervention
- Autologous tumor-infiltrating lymphocyte cells
- Study type
- Interventional
- Intervention type
- biological
- Primary sponsor
- Hervor Therapeutics
- Location
- Shenzhen,Nanjing,Hangzhou, China
- Phase
- Phase 1
- Start date
- May 30, 2023
- End date
- Dec 31, 2026
- Enrollment
- 15 participants
Safety of TIL
Background:
 
 Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by
 harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and
 then infusing back to patients.
 
 TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high
 objective response rates in multiple cancers, such as melanoma, NSCLC, and cervical cancer.
 
 Objective:
 
 To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor.
 
 Eligibility:
 
 Adults aging 18-75 with advanced solid tumor.
 
 Design:
 
 1. Patients will undergo screening tests, including imaging procedures, heart and lung
 tests, and lab tests.
 
 2. Freshly resected patient tumors were dissected by the surgeon.
 
 3. TIL cells were isolated from the patient's tumor tissue, then cultured in vitro,
 activated and expanded.
 
 4. At last TIL cells will be re-infused into the patients.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06334783
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06334783 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hervor Therapeutics and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.